New combo therapy targets hard-to-treat stomach cancer spread

NCT ID NCT07384234

Not yet recruiting Disease control Sponsor: Ruijin Hospital Source: ClinicalTrials.gov ↗

First seen Feb 03, 2026 · Last updated May 01, 2026 · Updated 5 times

Summary

This study is for people with stomach or gastroesophageal junction cancer that has spread to the lining of the abdomen (peritoneal metastasis). It tests whether adding the drug SHR-1701 to chemotherapy can help patients live longer and possibly become candidates for surgery. About 60 adults who have not had prior treatment will be randomly assigned to one of two drug combinations. The goal is to see if the new approach improves survival and tumor shrinkage.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GASTRIC ADENOCARCINOMA AND GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Changhai Hospital

Shanghai, Shanghai Municipality, China
Ruijin Hospital, Shanghai Jiaotong University School of Medicine

Shanghai, China

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact

Conditions

Explore the condition pages connected to this study.

GASTRIC ADENOCARCINOMA AND GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA